www.jmscr.igmpublication.org

Impact Factcor-1.1147 ISSN (e)-2347-176x



Evaluation of Risk Factors of Cardiovascular Disease on Hypertensive Post-Menopausal Women and Aged-matched Hypertensive Males

Authors

UK Amah¹, VE Obianyia², SC Meludu³, CE Onah^{*}, JM Olisakodiaka⁵, JA Onuegbu⁴, JE Okwara⁶, AK Amah⁷, EC Okwara⁸, AO Oluboyo⁹.

^{1,4,5,6}Department of Chemical Pathology, Faculty of Medicine, Nnamdi Azikiwe University, Nnewi Campus Anambra State, Nigeria.

^{2,9}Department of Medical Laboratory Sciences, Faculty of Health Sciences and Technology. Nnamdi Azikiwe University, Nnewi campus, Nnewi campus Anambra State, Nigeria.

³Department of Human Biochemistry, Faculty of Basic Medical Sciences, College of Health Sciences, Nnamdi Azikiwe University, Nnewi campus.

⁷Department of physiology, Faculty of Basic Medical Sciences, Imo State University Owerri, Imo State, Nigeria.

⁸Department of Chemical Pathology, Imo State University Teaching Hospital, Orlu, Imo State, Nigeria.

*Corresponding Author
Onah, Christian Ejike

Department of Chemical Pathology

Nnamdi Azikiwe University Teaching Hospital, Nnewi

Email: onamecwwide@yahoo.com.

Phone: +2348037326918

ABSTRACT

Background: This study compared plasma lipids and glucose levels in hypertensive post-menopausal women with age-matched hypertensive men. Methods: This is a cross sectional study that involves 100 subjects attending out-patient department of Nnamdi Azikiwe University Teaching hospital hypertensive clinics and control subjects. 25 hypertensive post-menopausal women and 25 hypertensive male subjects both within the same age range of 50-60 years. Also 25 hypertensive pre-menopausal women and 25 nonhypertensive controls both within the age range of 30-40 years. The lipid profile parameters (Total Cholesterol (TC), Triglyceride (TG), Low density Lipoprotein (LDL-C), and High Density Lipoprotein (HDL-C)) and fasting plasma glucose were determined using standard methods. The study also assessed the anthropometric indices such as BMI, SBP and DBP in each group. Results: The mean levels of TC and TG were significantly lower in post-menopausal hypertensive females when compared with the hypertensive males (p<0.05). However, the mean plasma HDL-C and LDL-C did not show any significant difference between the two groups. The comparison of the mean levels of all the parameters in hypertensive males with the non-hypertensive controls showed a significant difference (P < 0.05). The mean levels of TC and LDL-C were significantly higher in hypertensive post-menopausal women when compared with hypertensive pre-menopausal females (P<0.05). **Conclusion**: This study showed that menopause had altered the plasma lipids of the hypertensive post-menopausal women, but not to the extent of putting them at the same atherosclerosis scale as their male counterpart.

Key words: Hypertension, Menopause, Total cholesterol, Triglycerides.

INTRODUCTION

The traditional risk factors for atherosclerotic disease include age, gender, hypertension, body diabetes and smoking, mass index, hypercholesterolemia.[1] The female gender is considered a protective factor in the development of atherosclerosis.[2] Studies have shown that premenopausal women have more protective effect on the development of Coronary Heart Disease (CHD) when compared with both men of a similar age and postmenopausal women. [3-5] Estrogens affect the atherosclerotic process through a variety of mechanisms such as its lowering effect on total cholesterol and LDL-C,[6,7] Lipoprotein (a),[8] and its increasing effect on HDL-C.[9-11] Estrogen also has both acute vasodilatory effect on the vessel wall and an atheroprotective effect involving inhibition of smooth-muscle cell proliferation.[12]

The difference in cardiovascular risk between women and men at early ages disappears gradually after menopause and becomes equal for both sexes after ten years.[13-16] In this manner, cardiovascular diseases are considered to be the primary case of mortality in post-menopausal women.[17] Menopausal status is accompanied by unfavorable levels of cardiovascular risk factors, like changes in body fat, distribution from gynoid to android pattern, abnormal plasma lipids, increased sympathetic tone, endothelial dysfunction, vascular inflammation, and increased blood pressure.[18] Recently, postmenopausal women were reported to have the same prevalence of sub clinical carotids atherosclerosis as men matched with age and traditional risk factors.[19] Study also shows that oestrogen does not appear provide cardiovascular postmenopausal women with established coronary heart disease.[20] Moreover, it has been reported

that more post-menopausal female record an increased incidence of cardiovascular conditions.[17] The reason for this change in disease amongst women is not entirely clear, though however, it may be the observed association between atherosclerosis and hyperlipidemia.

Today, more African women live beyond 50 years, that is, post-menopause, a factor which should further heighten the risk of cardiovascular disease in them. As women age, their health is influenced by factors such as career, diet, physical activity level, the socioeconomic status and environment.[21] These changes, together with natural menopause, process of ageing, and hormonal changes in the reproductive system, affect the well-being of women.[22] The complex, interrelated nature of the process often makes it difficult to distinguish between the symptoms of ageing or those resulting from the loss of overian functions, factors arising and socioenvironmental conditions. Thus, we decided to compared men and women of the same age, traditional risk factors and socioeconomic and environmental status in other to ascertain their atherosclerosis status based on their lipid profile and glucose levels. It is hoped that the outcome of this study would improve our understanding of growing subject and also management of menopause for which hormone replacement therapy is already being tried as a preventive measure against ischaemic heart disease arising from hyperlipidaemia.

METHODS

Study population and Design:

A total of 100 subjects, comprising 25 hypertensive post-menopausal women and 25 hypertensive men, both within the age bracket of 50-60yrs, and 25 hypertensive pre-menopausal women and 25 non hypertensive (men and women) both within the age bracket of 30-40yrs. They were all recruited after taking a thorough clinical history. Hypertensive women aged between 50 and 60 years, with absence of menstrual cycles for at least one year, were included. In all the groups, those that have any history of chronic illness, had undergone hysterectomy, and on hormone replacement

therapy, were excluded from the study. The informed consent was obtained from all the participants, and the experimental protocol was approved by the Ethics committee of Nnamdi Azikiwe University Teaching Hospital, Nnewi.

All the participants were instructed to refrain from food, alcohol and tobacco for 12 hours prior to recording and sample collection. They all underwent measurement of height, weight and basal blood pressure. Height was measured to the nearest 0.1 cm without footwear, using vertically movable scale. Weight was measured to the nearest 100 grams using a digital scale. A basal recording of blood pressure was done using Automatic Blood Pressure Monitor.

Sample Collection and Biochemical Analysis

5 mls of fasting venous blood samples were collected from all respondents for the analysis. A part was dispensed into fluoride oxalate bottles for glucose determination using standard enzymatic spectrophotometric method (Glucose Oxidase method). The remaining part was dispensed into a Na-EDTA bottle and the plasma separated and stored at -20°C until analysis of Lipid profile.

The total cholesterol (TC) was estimated using enzymatic endpoint method. The cholesterol is determined after enzymatic hydrolysis and oxidation. The indicator quinoneimine is formed from hydrogen peroxide and 4 - aminoantipyrine in the presence of phenol and peroxidase.

High Density Lipoprotein (HDL) was estimated using enzymatic method. Low density lipoprotein (LDL and VLDL) and chylomicron fractions are precipitated quantitatively by the addition of phosphotungstic acid in the presence of magnesium ions. After centrifugation, the cholesterol concentration in the HDL fraction, which remains in the supernatant was determined. Triglyceride (TG) was estimated using enzymatic method. The triglycerides are determined after enzymatic hydrolysis with lipases. The indicator is a quinoneimine formed from hydrogen-peroxide, 4-aminophenazone and 4-chlorophenol under the catalytic influence of peroxidase.

Glucose was estimated using glucose oxidase method. Glucose in plasma reacts with oxygen to give gluconic acid and hydrogen peroxide. This reaction is catalyzed by glucose oxidase enzyme. The hydrogen peroxide oxidizes the chromogen (4)

All data were expressed as the mean \pm standard deviations. The test of significant difference

between two groups was done by the student T-

test with p<0.05 being the cut-off point of

- aminophenazone) in the presence of the enzyme peroxidase to give a colored compound that was measured spectrophotometrically.

The LDL-C was calculated by the previously established formula of friedwald. Body mass indix was calculated from measured height and weight. The TC: HDL ratio and averages (mean + SD) were determined.

Statistical Analysis

The version 20 of Statistical Package for Social Sciences (SPSS) was used in statistical analysis.

RESULTS

The comparison of the mean levels of parameters between the hypertensive post-menopausal women and those of their male counterparts showed significant difference (p<0.05) in levels of triglycerides and total cholesterol. However, the results showed no statistical significant difference in the levels of age, BMI, HDL-C. LDL-C, TC: HDL, FBG, systolic BP, and diastolic BP in these two groups (Table 1).

significant.

Table 1. The mean levels of some parameters in the Hypertensive post-menopausal women and those of their male counterpart.

	POST-	MALES	P
PARAMETE	MENO	(25)	=VALU
RS	(25) mean	means <u>+</u>	ES
	<u>+</u> SD	SD	
AGE (yrs)	57.68 <u>+</u>	57.80 <u>+</u>	1.000
	2.45	2.45	
BMI (kgm ⁻²)	28.51 <u>+</u>	26.60 <u>+</u>	0.080
	1.59	1.80	
TC (mmoL/L)	5.21 <u>+</u>	5.92 <u>+</u>	0.004
	0.81	0.47	
HDL-C	1.15 <u>+</u>	1.03 <u>+</u>	0.722
(mmol/L)	0.32	0.28	
LDL-C	3.37 <u>+</u>	4.06 <u>+</u>	0.388
(mmol/L)	0.44	0.62	
TG (mmol/L)	0.99 <u>+</u>	1.64 <u>+</u>	0.000
	0.04	0.36	
TC:HDL	4.78 <u>+</u>	6.21 <u>+</u>	0.104
	1.13	1.90	
FBG	5.39 <u>+</u>	5.8 ± 2.75	0.829
(mmol/L)	1.78		
Systolic BP	174.80 <u>+</u>	176.16 <u>+</u>	0.987
(mmHg)	15.08	20.82	
Diastolic BP	107.80 <u>+</u>	105.40 <u>+</u>	0.862
(mmHg)	13.03	15.06	

The comparison of the mean levels of the parameters between the hypertensive post-menopausal women and those of hypertensive pre-menopausal women showed that there was statistical significant difference (p<0.05) between the mean levels of age, TC, LDL-C, FBG, systolic BP, and diastolic BP of the

hypertensive post-menopausal and that of hypertensive pre-menopausal women. The result also showed that there was no statistical significant different (p>0.05) between the mean levels of BMI, HDL-C, TC: HDL and FBG, of the hypertensive post-menopausal women and that of hypertensive pre-menopausal women (Table 2).

Table 2. The mean levels of the some parameters of the hypertensive post-menopausal women and those of the hypertensive pre-menopausal women.

PARAMETE	POST-	PRE-	P-
RS	MENO	MENO	VALUE
	(25)	(25)	S
	mean <u>+</u>	mean <u>+</u> SD	
	SD		
AGE (yrs)	57.68 <u>+</u>	38.68 <u>+</u>	0.000
	2.75	1.84	
BMI (kgm ⁻²)	28.51 <u>+</u>	26.75 <u>+</u>	0.123
	1.59	1.83	
TC (mmol/L)	5.21 <u>+</u>	4.89 <u>+</u> 0.65	0.000
	0.81		
HDL-C	1.15 <u>+</u>	1.25 ± 0.37	0.826
(mmol/L)	0.32		
LDL-C	3.75 <u>+</u>	3.04 ± 0.06	0.03
(mmol/L)	0.44		
TG (mmol/L)		1.65 ± 0.62	0.000
	0.40		
TC:HDL	4.78 <u>+</u>	4.21 <u>+</u> 1.29	0.795
	1.13		
FBG	5.39 <u>+</u>	4.55 <u>+</u> 1.09	0.336
(mmol/L)	1.78		
Systolic BP	174.80 <u>+</u>	150.52 <u>+</u>	0.000
(mmHg)	15.08	8.14	
Diastolic BP	107.80 <u>+</u>	93.64 <u>+</u>	0.000
(mmHg)	3.09	3.09	

The comparison of the mean levels of the parameters between the hypertensive post-menopausal women and those of the non-hypertensive control individuals shows that there is statistical significance difference (p<0.05) between the mean levels of age, BMI, TC, HDL-C, LDL-C, systolic BP and diastolic BP of the hypertensive post-menopausal women and that of non-hypertensive control individuals. The result also shown that there were no statistical significant differences between the levels of TG, TC:HDL, and FBG of the hypertensive post-menopausal women and that of non-hypertensive control individuals (Table 3).

Table: 3. The mean levels of some parameters of the hypertensive post-menopausal women and those of non-hypertensive control individuals.

PARAME	POST-	CONTRO	P-
TERS	MENO	L	VALU
	N = 25	N = 25	E
AGE (yrs)	57.68 <u>+</u> 2.75	43.00 <u>+</u>	0.000
		8.94	
BMI	28.51 <u>+</u> 1.59	23.92 <u>+</u>	0.000
(kgm -2)		4.68	

TC	5.21 + 0.81	4.50 + 0.86	0.004
(mmol/L)	_	_	
HDL-C	1.15 ± 0.32	1.45 ± 0.60	0.018
(mmol/L)			
LDL-C	3.75 ± 0.44	2.25 <u>+</u> 1.01	0.000
(mmol/L)			
TG	0.99 ± 0.04	1.22 ± 0.54	0.354
(mmol/L)			
TC:HDL	4.78 <u>+</u> 1.13	3.97 <u>+</u> 3.58	0.569
FBG	5.39 <u>+</u> 1.78	4.19 ± 0.74	0.082
(mmol/L)			
SBP	1.74.80 <u>+</u>	115.36 <u>+</u>	0.000
(mmHg)	15.08	952	
DBP	107.80 <u>+</u>	70.88 <u>+</u>	0.000
(mmHg)	13.03	7.94	

The comparison of the mean levels of the parameters between the hypertensive males and those of the non-hypertensive control individuals shows that there were statistical significant difference (p<0.05) between the mean levels of the all the parameters in hypertensive males and that of the non-hypertensive males control individuals (Table 4).

Table 4. The mean levels of some parameters of the hypertensive males and those of the non-hypertensive control individuals.

PARAMETE	MALES	CONTROL	P-
RS	N = 25	S	VALU
		N = 25	ES
Age (yrs)	57.80 <u>+</u>	43.00 <u>+</u>	0.000
	2.45	8.94	
BMI (kgm ⁻²)	26.60 <u>+</u>	23.92 <u>+</u>	0.005
	1.80	4.68	
TC (mmol/	5.92 <u>+</u>	4.50 ± 0.86	0.000
L)	0.47		
HDL-C	1.03 <u>+</u>	1.45 ± 0.60	0.001
(mmol/L)	0.28		
LDL-C	4.06 <u>+</u>	2.25 ± 1.01	0.000
(mmol/L)	0.62		
TG (mmol/L)	1.64 <u>+</u>	1.22 ± 0.54	0.015
	0.36		
TC:HDL	6.21 <u>+</u>	3.94 <u>+</u> 3.58	0.003
	1.90		
FBG	5.82 <u>+</u>	4.19 ± 0.74	0.008
(mmol/L)	2.75		
Systolic BP	176.16 <u>+</u>	115.36 <u>+</u>	0.000
(mmHg)	20.82	9.52	
Diastolic BP	105.40 <u>+</u>	70.88 <u>+</u>	0.000
(mmHg)	7.94	7.94	

DISCUSSION

This study showed that the levels of TG and TC are significantly lower in hypertensive post-menopausal women than in their male counterpart. This shows that there is a lower tendency for hypertensive post-menopausal females to develop atheroma than males of their age. This outcome agrees with the situation reported in pre-menopausal hypertensive females, which showed that hypertensive child-bearing females stood less risk of atherosclerotic diseases, compared with men their age. [23] It also agrees with the findings in normal post-menopausal females, which reported that normal postmenopausal women, by plasma lipid analysis, stand less risk of atheroma-formation than their male counterparts. [24]

The female gender already largely shields these females from the risk of atheroma formation.[2] To further favour the females, oestrogen is known to have an inverse relationship with plasma lipid level.[25] Estrogens affect the atherosclerotic process through a variety of mechanisms such as its lowering effect on total cholesterol and LDL,[6,7] Lipoprote in (a),[8] and its increasing effect on HDL.[9,10] Estrogen also has both acute vasodilatory effect on the vessel wall and an atheroprotective effect involving inhibition of smoothmuscle cell proliferation.[12] Though menopause is associated with waning influence of oestrogen, aromatization in peripheral fatty tissues could partly sustain the oestrogen influence far into the postmenopausal period. This may be in operation in Nigeria females, with a BMI above pre-menopausal values.

Furthermore, the comparison between hypertensive post-menopausal women and non-hypertensive controls, and also between hypertensive men and nonhypertensive controls showed that both postmenopausal women and their male counterpart are at risk of developing CHD but tends to be more among hypertensive men. This is because all the parameters analyzed in this study were significantly higher in hypertensive men than in non-hypertensive controls, while there is no significant difference in the mean levels of triglyceride, TC:HDL, and fasting plasma glucose in hypertensive post-menopausal women and non-hypertensive controls. Thus, putting hypertensive post-menopausal women less in the atherosclerosis scale than their male counterpart.

This study also showed that the level of LDL-C and cholesterol are significantly higher in hypertensive post-menopausal women than in hypertensive premenopausal women. This is in line with some studies that showed that pre-menopausal women have more protective effect on the development of CHD when compared with both men of a similar age and

postmenopausal women.[3,5] Factors that may partly explain the positioning of the post-menopausal women on the atheroma scale than pre-menopausal women would include age,[1] higher BMI, diminishing oestrogen effect[23] and duration of the hypertension. These findings supported our present study as our results showed significantly higher levels of BMI, SBP, DBP, and age in post-menopausal women than in pre-menopausal women.

CONCLUSION

In conclusion, this study showed that menopause had altered the plasma lipids of the hypertensive females, but not to the extent of putting them at the same level of atherosclerosis risk scale as their male counterpart.

REFERENCES

- 1. Cizek SM, Bedri S, Talusan P, Siwa N, Lee H, Stone JR. Risk factors for atherosclerosis and development of pre atherosclerotic initial hyperplasia. Public medicine. 2007;16(6):344-350.
- 2. Taguchi K, Matsumoto T, Kamata K, Kobayashi T. Akt/eNos pathway activation in female and male. Public medicine. 2011;65(1):56-65.
- 3. Hu FB, Grodstein F, Hennekens CH, Colditz GA, Johnson M, Manson JE, et al. Age at natural menopause and risk of cardiovascular disease. Arch Intern Med 1999;159:1061-1066.
- 4. Barrett CE, Bush TL. Estrogen and coronary heart disease in women. J Am Med Assoc 1991;265:1861-1867.
- 5. Van der Schouw YT, van der GY, Steyerberg EW, Eijkemans JC, Banga JD. Age at menopause as a risk factor for cardiovascular mortality. Lancet 1996;347: 14-718
- 6. Tremollieres FA, Pouilles JM, Cauneille C, Ribot C. Coronary heart disease risk factors and menopause: a study in 1684 French women. Atherosclerosis 1999;142:415-423.
- 7. Davis CE, Pajak A, Rywik S, Williams DH, Broda G, Pazucha T, et al. Natural menopause and cardiovascular disease risk factors. The Poland and US Collaborative Study on Cardiovascular Disease

- Epidemiology. Ann Epidemiol 1994;4:445-448.
- 8. Brown SA, Morrisett JD, Boerwinkle E, Hutchinson R, Patsch W. The relation of lipoprotein(a) concentrations and apolipoprotein(a) phenotypes with asymptomatic atherosclerosis in subjects of the Atherosclerosis Risk in Communities (ARIC) Study. Arterioscler Thromb 1993;13:1558-1566.
- 9. Herrington MD, Reboussin DM, Brosnihan KB, Sharp PC, Shumaker SA, Snyder TE, et al. Effects of estrogen replacement on the progression of coronary-artery atherosclerosis. N Engl J Med 2000;343:522-529.
- Darj E, Crona N, Nilsson S. Effects on lipids and lipoproteins in women treated with oestradiol and progesterone. Maturitas 1992;15:209-215.
- 11. Hulley S, Grady D, Bush T, Furberg C, Herrington D, Riggs B, et al. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and Estrogen/Progestin Replacement Study (HERS) Research Group. J Am Med Assoc 1998;280:605-613.
- 12. Mendelsohn ME, Karas RH. Estrogen and the blood vessel wall. Curr Opin Cardiol 1994;9:619-626.
- 13. Rumeau-Rouquette C, Bouvier-Colle MH, Ringa V, Saurel-Cubizolles MJ. Women's Health. Oxford Textbook of Public Health. Third Edition. Detels R, Holland WW, McEwen J, Omenn GS, eds. Oxford University Press, Oxford 1997; 1355-78.
- 14. Ko GT, Chan JC, Woo J, Lau ED, Yeung VTF, Chow C, et al. The effect of age on cardiovascular risk factors in Chinese women. Int J Cardiol 1997;61:221-7.
- 15. Brezinka V, Padmos I. Coronary heart disease risk factors in women. Eur Heart J 1994;15:1571-84.
- 16. Corrao JM, Becker RC, Ockene IS, Hamilton GA. Coronary heart disease risk factors in women. Cardiology 1990;77:8-24.

- 17. Sekuri C, Eser E, Akpinar G, Cakir H, Sitti I, Gulomur O, et al. Cardiovascular Disease Risk Factors in Post-Menopausal Women in West Anatolia: A Rural Region Prevalence Study. Jpn Heart J 2004;45:119-131.
- 18. Rosano GMC, Vitale C, Marazzi G, Volterrani M. Menopause and cardiovascular disease: the evidence. Climacteric 2007;10:19-24.
- 19. Stamatelpoulos KS, Armeni E, Georgiopoulos G, Kazani M, Kyrkou K, Stellos K, et al. Recently postmenopausal women have the same prevalence of subclinical carotid atherosclerosis as age and traditional risk factor matched men. Atherosclerosis 2012;221:508-513.
- 20. Herrington DM, Reboussin DM, Brosnihan KB. Effect of oestrogen replacement on the progression of coronary-artery atherosclerosis. N Engl J med. 2000;343(1):522-529.
- 21. Farag NH, Bardwell WA, Nelesen RA, Dimsdale JE, Mills PJ. Autonomic responses to psychological stress: the influence of menopausal status. Annals of Behavioral Medicine 2003;26:134-138.
- 22. Narayanaswamy N, Moodithaya S, Halahalli H, Mirajkar AM. Assessment of Risk Factor for Cardiovascular Disease using Heart Rate Variability in Postmenopausal Women: A Comparative Study between Urban and Rural Indian Women. Cardiology 2013;2013:1-6.
- 23. Jarikre AE, Dim DC, Ajuluchukwu JNA. Plasma Lipid Levels in Nigerian hypertensives. The gender factor. Nigerian Journal Hospital Medicine. 2010;6(4):293-298
- 24. Oke DA, Jarikre AE, Idogun SE. Interpreting plasma lipid profiles in Nigerisn Africans by the total cholesterol to high density lipoprotein cholesterol ratio Nigerian journal internal Medicine. 2009;2(3):92-94.
- 25. Schufelt CL, Johnson BD, Berga SL.Timing of hormone therapy, type of menopause and coronary disease. Menopause. 2011;18(1):943-950.